Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 16;23(10):5533. doi: 10.3390/ijms23105533

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The effect of PXS-5505 treatment on CCl4-induced liver fibrosis and collagen crosslinks in mouse lung. (A) Representative images of liver stained with Picro-Sirius red, differentiating collagen (red) from hepatocytes (yellow) with quantification of the staining area, showing significantly elevated percentage of collagen deposited area in the mice administered with CCl4 compared to the normal mice, and the fibrotic area reduced in the CCl4 group subjected to PXS-5505 treatment compared to the vehicle treated group. (B) CCl4 administration elevated the expression of hydroxyproline (HYP), immature [dihydroxy-lysinonorleucine (DHLNL) and hydroxylysinonorleucine (HLNL)] and mature [pyridinoline (PYD)] collagen crosslinks in the mouse liver; PXS-5505 treatment ameliorated these elevated markers induced by CCl4. (* p < 0.05, ** p < 0.01, *** p < 0.001 between the indicated groups).